Literature DB >> 22619171

Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Kwang Soo Kim1, Yu Ree Choi, Ji-Young Park, Jung-Ho Lee, Dong Kyu Kim, Seung-Jae Lee, Seung R Paik, Ilo Jou, Sang Myun Park.   

Abstract

Parkinson disease (PD) is the second most common neurodegenerative disease characterized by a progressive dopaminergic neuronal loss in association with Lewy body inclusions. Gathering evidence indicates that α-synuclein (α-syn), a major component of the Lewy body, plays an important role in the pathogenesis of PD. Although α-syn is considered to be a cytoplasmic protein, it has been detected in extracellular biological fluids, including human cerebrospinal fluid and blood plasma of healthy and diseased individuals. In addition, a prion-like spread of α-syn aggregates has been recently proposed to contribute to the propagation of Lewy bodies throughout the nervous system during progression of PD, suggesting that the metabolism of extracellular α-syn might play a key role in the pathogenesis of PD. In the present study, we found that plasmin cleaved and degraded extracellular α-syn specifically in a dose- and time- dependent manner. Aggregated forms of α-syn as well as monomeric α-syn were also cleaved by plasmin. Plasmin cleaved mainly the N-terminal region of α-syn and also inhibited the translocation of extracellular α-syn into the neighboring cells in addition to the activation of microglia and astrocytes by extracellular α-syn. Further, extracellular α-syn regulated the plasmin system through up-regulation of plasminogen activator inhibitor-1 (PAI-1) expression. These findings help to understand the molecular mechanism of PD and develop new therapeutic targets for PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619171      PMCID: PMC3408156          DOI: 10.1074/jbc.M112.348128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

3.  Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.

Authors:  Jeffrey H Kordower; Yaping Chu; Robert A Hauser; Thomas B Freeman; C Warren Olanow
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

4.  Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.

Authors:  M D Ledesma; J S Da Silva; K Crassaerts; A Delacourte; B De Strooper; C G Dotti
Journal:  EMBO Rep       Date:  2000-12       Impact factor: 8.807

5.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.

Authors:  J Li; V N Uversky; A L Fink
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

6.  The plasmin system is induced by and degrades amyloid-beta aggregates.

Authors:  H M Tucker; M Kihiko; J N Caldwell; S Wright; T Kawarabayashi; D Price; D Walker; S Scheff; J P McGillis; R E Rydel; S Estus
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

7.  Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.

Authors:  Takashi Kasai; Takahiko Tokuda; Nozomi Yamaguchi; Yoshihisa Watanabe; Fuyuki Kametani; Masanori Nakagawa; Toshiki Mizuno
Journal:  Neurosci Lett       Date:  2008-03-04       Impact factor: 3.046

8.  Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species.

Authors:  Daniel Sevlever; Peizhou Jiang; Shu-Hui C Yen
Journal:  Biochemistry       Date:  2008-08-15       Impact factor: 3.162

9.  Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.

Authors:  Ji-Young Park; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  Glia       Date:  2008-08-15       Impact factor: 7.452

10.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.

Authors:  Jia-Yi Li; Elisabet Englund; Janice L Holton; Denis Soulet; Peter Hagell; Andrew J Lees; Tammaryn Lashley; Niall P Quinn; Stig Rehncrona; Anders Björklund; Håkan Widner; Tamas Revesz; Olle Lindvall; Patrik Brundin
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

View more
  23 in total

Review 1.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 2.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 3.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

4.  Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Authors:  Meike Diepenbroek; Nicolas Casadei; Hakan Esmer; Takaomi C Saido; Jiro Takano; Philipp J Kahle; Ralph A Nixon; Mala V Rao; Ronald Melki; Laura Pieri; Stefan Helling; Katrin Marcus; Rejko Krueger; Eliezer Masliah; Olaf Riess; Silke Nuber
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

5.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 6.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

7.  Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.

Authors:  Fares Bassil; Pierre-Olivier Fernagut; Erwan Bezard; Alain Pruvost; Thierry Leste-Lasserre; Quyen Q Hoang; Dagmar Ringe; Gregory A Petsko; Wassilios G Meissner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

Review 8.  Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.

Authors:  Manuel Yepes; Yena Woo; Cynthia Martin-Jimenez
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 9.  Proteolytic α-Synuclein Cleavage in Health and Disease.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan von Hörsten; Anja Schulze; Steffen Roßner
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

10.  The neuroendocrine protein 7B2 is intrinsically disordered.

Authors:  Indrani Dasgupta; Laura Sanglas; Jan J Enghild; Iris Lindberg
Journal:  Biochemistry       Date:  2012-09-14       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.